aTyr Pharma, Inc.
ATYR
$5.35
$0.408.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.10% | -17.58% | -27.06% | -47.89% | -28.51% |
| Total Depreciation and Amortization | -54.68% | -58.16% | -43.82% | -35.73% | 4.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 400.49% | 217.86% | 148.21% | -174.65% | -148.62% |
| Change in Net Operating Assets | 207.09% | 69.77% | -146.08% | -168.06% | -223.14% |
| Cash from Operations | 12.37% | -12.99% | -108.06% | -106.13% | -80.00% |
| Capital Expenditure | 91.82% | 98.39% | 98.46% | 98.93% | 88.45% |
| Sale of Property, Plant, and Equipment | -- | -53.33% | -53.33% | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -61.72% | -27.72% | 208.56% | 234.42% | 294.04% |
| Cash from Investing | -61.04% | -15.10% | 185.62% | 214.44% | 240.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -10.71% | -12.92% | -26.14% | -40.29% | -97.05% |
| Issuance of Common Stock | 84.00% | 105.79% | -39.42% | -55.17% | -50.86% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 85.15% | 107.50% | -39.81% | -55.72% | -51.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 272.39% | 120.00% | -193.32% | 115.57% | -192.57% |